

# Novel Pathways Implicated in the Seladelpar-mediated Reductions of Established Liver Fibrosis are Identified from RNAseq Data using Plex Search and Two Independent Mouse Pharmacology Datasets




Edward E. Cable<sup>1</sup>, Douglas W. Selinger<sup>2</sup>, Yun-Jung Choi<sup>1</sup>, Charles A. McWherter<sup>1</sup>  
<sup>1</sup>CymaBay Therapeutics (Newark, CA) and <sup>2</sup>Plex Research (Cambridge, MA)




## Background and Aims


Seladelpar reduces established liver fibrosis in multiple mouse models, despite differences in fibrotic stimuli. Using previously existing unbiased RNAseq datasets from two different models, the top 100 changed genes from both studies were used as queries in Plex search, an AI based search engine. The AIM was to identify seladelpar-regulated protein families common to both models. Assumption: MOA for seladelpar-mediated reduction of fibrosis utilizes common pathway(s).



## Introduction - Studies



## Workflow and Graphical Results






n=100 each query  
G = Gubra, D = Decreased, Q = Query  
C = CCl4, I = Increased, R = Results

**New Hypothesis:**  
Seladelpar reduces established liver fibrosis in mice via reduction of lipocalin 2 and/or serpin clade A.



**Plex**  
Knowledge graph based search engine that allows multiple query types, including chemical structure, genes, and perturbations. In this case lists of 100 RNA transcripts were used to ask: Where has a similar gene signature been observed? Do they represent a common protein family? The Plex knowledge graph contains >500M data points and covers diverse experimental and curated data sources including multi-omics, pharmacology, clinical, and public domain databases.

**Seladelpar Results**  
2018 AASLD  
2019 Keystone  
2019 EASL  
2021 EASL  
2022 EASL  
Contact Information  
Ed Cable - CymaBay  
ecable@cymabay.com  
Doug Selinger - Plex  
dselinger@plexresearch.com  
www.plexresearch.com




Despite the small overlap in the query sequences, the protein family results indicate congruent pharmacology as indicated by the similarity of decreased genes. Liver fibrosis is decreased in both models, in the presence of the fibrotic stimuli, we further analyzed the common protein families and assessed the known connections to fibrosis, if any.

## Lipocalins and Major Urinary Proteins (MUPs)



Conserved family of serine (or cysteine) peptidase inhibitors (3). May also play important signaling functions within cells. Biological roles of serpins and selected serpin isoforms are not well characterized.




All expressed family members shown in the graphs, ranked by expression in the vehicle group. Color coding indicates decreased, no change, or increased. Top 10, Veh vs Tx shown in individual graphs for each experiment. Clade A serpins are the highest expressing serpins and the majority are decreased by seladelpar. Clade B are the next most numerous and generally unaffected by seladelpar. The role(s) serpins in liver fibrosis is generally unknown.

## Conclusions

Assuming a common MOA for seladelpar-mediated reductions of established liver fibrosis in disparate murine models: Counterintuitively, the two protein families with established literature connections to fibrosis were reduced by seladelpar. Lipocalin 2 and SERPIN clade A. **LCN2 is positively correlated and mechanistically linked with fibrosis (2). SERPINS are proteins that inhibit proteases (under certain conditions).** Further experiments are required to elucidate the mechanism(s) by which LCN2 and SERPINS are related to seladelpar-mediated reduction of established liver fibrosis in murine models.

## Note of Interest

LCN2 has been implicated in the profibrotic phenotype in cholestatic liver disease (4). A recent review (5)  
**References and QR code**  
1. Charkoftaki (2019) 30782214  
2. Chen (2020) 32968110  
3. Bouton (2023) 37158379  
4. O'Brien (2022) fscbj.2022.36.S1.R5479.  
5. Sanrattana (2019) 30809526



Download a PDF version of this poster directly from the CymaBay website by scanning the QR code. The PDF version contains active links for emails, URLs and references. The references are the PMID numbers where available. Links on the left lead to previous posters presented by CymaBay. The posters will download the respective PDFs from the CymaBay website.